First bapi; now neuroscience puts stem cells on trial in autism
This article was originally published in Scrip
Executive Summary
Researchers at Sutter Neuroscience Institute in Sacramento, California will run a first-of-its-kind US FDA-endorsed Phase II clinical trial in which autistic children between the ages of 2 and 7 will be treated with stem cells derived from their own umbilical cord blood to see if the therapy improves their language skills and behavior.